Summary
Nine patients with metastatic breast cancer received 30 × 106 I.U. of Interferon — Betaser (Betaseron) intravenously daily times five for two consecutive weeks followed by a two week rest period. Only one patient received more than one such cycle of Betaseron. The drug was well tolerated in eight of these patients. One patient, with liver metastases and liver dysfunction, developed hepatic decompensation during therapy. Toxicity consisted of anorexia, chills, fever, fatigue and nausea with an occasional patient having emesis. One patient developed severe thrombocytopenia, two, significant leukopenia and nine, mild elevations of serum transaminase. Two patients developed beta interferon binding antibodies but none developed neutralizing antibodies. No anti-tumor responses were seen and disease progression occurred rapidly during the four week cycle in eight of nine patients.
Similar content being viewed by others
References
Kirkwood JM, Ernstoff MS: Interferons in the treatment of human cancer. J Clin Oncol 2:336–352, 1984
Hayward JL, Carbone PP, Heuson JL, Kumaoka S, Segaloff A, Reubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39:1289–1294, 1977
Quesada J, Gutterman JU, Hersh EM: Clinical and immunological study of beta interferons by intramuscular route in patients with metastatic breast cancer. J Interferon Res 2:593–599, 1982
Pouillart P, Palangie T, Jouve M, Garcia-Giralt E, Fridman WH, Magdelenat H, Falcoff E, Billiay A: Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastases and on hormone receptors. Eur J Cancer Clin Oncol 18:929–935, 1982
Horoszewicz JS, Leong SS, Ito M, Buffett R, Karakousis C, Holyoke E, Job I, Dolan J, Carter WA: Human fibroblast interferon in human neoplasia: clinical and laboratory study. Cancer Treat Rep 11:1899–1906, 1978
Bruntsch U, Groos G, Tiggs FJ, Hofschneider PH, Gallmeier WM: Lack of response in nine patients with breast cancer treated with fibroblast interferon. Cancer Chemother Pharmacol 13:39–42, 1984
Sarna G, Pertcheck M, Figlin R, Ardalan B: Phase I study of recombinant Betaser 17 interferon in the treatment of cancer. Cancer Treat Rep 70:1365–1372, 1986
Hawkins M, Horning S, Konrad M, Anderson S, Sielaff K, Rosno S, Schiesel J, Davis T, Demets D, Merigan T, Borden E: Phase I evaluation of a synthetic mutant of beta-interferon. Cancer Res 45:5914–5920, 1985
Chang AYC, Pandya KJ, Asbury RF, Carignan J, Woll J, Storer B, Merritt JA, Bennett JM: Phase I study of recombinant beta interferon in cancer patients by subcutaneous injection. Proc Am Soc Clin Oncol (abst.) 4:226, 1985
Chang AYC, Asbury RF, McCune C, Woll J, Pandya KJ, Bennett JN, Storer B: Phase I study of human recombinant beta interferon (Ifn-Betaser) in cancer patients by intramuscular injections (IM). Proc Am Soc Clin Oncol (abst.) 5:233, 1986
Dimitrov NV, Myer C, Strander H, Einhorn S, Cantell K: Interferon as modifier of estrogen receptors. Ann of Clin and Lab Sci 14:32–39, 1984
Sica G, Natoli V, Stella C, Dell Bianco S: Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 60:2419–2423, 1987
Davidson HS, Schilsky RL, Golomb HM: Gonadal and sexual function following treatment of hairy cell leukemia with recombinant alpha-2-interferon. Proc Am Soc Clin Oncol (abst.) 4:232, 1985
Schiller JH, Groveman DS, Schmid SM, Willson JKV, Cummings KB, Borden EC: Synergistic anti-proliferative effects of recombinant a54- or Betaser with gamma interferons on human cell lines of various histogenesis. Cancer Res 46:483–488, 1986
Krown SE: Interferons: Not just alpha. Cancer Treat Rep 70:1353–1355, 1986
Krigel R, Poiesz B, Comis R, Rudolph A: A Phase I study of recombinant interleukin-2 plus recombinant betaser 17 interferon. Proc Am Soc Clin Oncol (abst.) 5:225, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barreras, L., Vogel, C.L., Koch, G. et al. Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer. Invest New Drugs 6, 211–215 (1988). https://doi.org/10.1007/BF00175400
Issue Date:
DOI: https://doi.org/10.1007/BF00175400